General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Share ownership

The information in the following tables relates only to registered
shareholders and does not include holders of unregistered shares.

Also, the information provided in the tables below cannot be
assumed to be representative of the entire Novartis investor base
since nominees and JPMorgan Chase Bank, as ADS depositary, are
registered as shareholders for a large number of beneficial owners.

As of December 31, 2012, Novartis had approximately 161 000 registered shareholders.

Registered shareholder types (in %)

Individual shareholders: 12.08% ; Legal entities: 37.26% ; Nominies, fiduciaries and ADS depositary: 12.08%

Registered shares by country (in %)

Switzerland: 42.13% ; Germany: 3.55% ; United States: 46.24% ; France: 1.31% Germany: 3.55% UK: 2.75% Other countries: 4.02%
Stock chart